Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.73 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | CDC42 | P60953 | 1/20 | 0.73 |
| ▸ | RAC1 | P63000 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9284416 | 0.87 | TDP1 (1.00) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| Naproxen SCHEMBL29350675 | 0.85 | AKR1C3 (1.00) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| Naproxen SCHEMBL616149 | 0.85 | AKR1C3 (1.00) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| Naproxen SCHEMBL30346195 | 0.85 | AKR1C3 (1.00) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| Naproxen SCHEMBL215236 | 0.85 | AKR1C3 (1.00) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| Naproxen SCHEMBL10029028 | 0.85 | AKR1C3 (1.00) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| Naproxen SCHEMBL3046 | 0.85 | AKR1C3 (1.00) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| Naproxen SCHEMBL42434 | 0.85 | AKR1C3 (1.00) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| Naproxen SCHEMBL29360045 | 0.85 | AKR1C3 (1.00) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| Naproxen SCHEMBL29359528 | 0.85 | AKR1C3 (1.00) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9144579-B2 | Polyesters and methods of use thereof | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140050692-A1 | POLYESTERS AND METHODS OF USE THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050692-A1 | POLYESTERS AND METHODS OF USE THEREOF | TLR3, PTGES3, CD68 | TDP1 1747/4885L3MBTL1 2952/4885AKR1C3 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.